Skip Navigation

Annals of Oncology 2007 18(3):504-509; doi:10.1093/annonc/mdl430
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kwon, H-C
Right arrow Articles by Kim, H-J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwon, H-C
Right arrow Articles by Kim, H-J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

gastrointestinal tumors

Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer

H-C Kwon1, MS Roh2, SY Oh1, S-H Kim1, MC Kim3, J-S Kim1 and H-J Kim1,*

1 Department of Internal Medicine
2 Department of Pathology
3 Department of Surgery, Dong-A University College of Medicine, Busan, Korea

* Correspondence to: Prof H.-J. Kim, Department of Internal Medicine, Dong-A University College of Medicine, 3-1 Dongdaeshin-dong, Seo-gu, Busan 602-715, Korea. Tel: +82-51-240-2951; Fax: +82-51-240-2951; E-mail: kimhj{at}dau.ac.kr

Background: The aim of this study was to determine whether expressions of the excision repair cross-complementing (ERCC1), thymidylate synthase (TS), and glutathione S-transferase P1 (GSTP1) predict clinical outcome in patients with advanced gastric cancer treated with fluorouracil (5-fluorouracil)/oxaliplatin chemotherapy.

Patients and methods: The study population consisted of 64 advanced gastric cancer patients (median age 51 years). Patients were treated with oxaliplatin 85 mg/m2 as a 2-h infusion at day 1 plus leucovorin 20 mg/m2 over 10 min, followed by 5-FU bolus 400 mg/m2 and 22-h continuous infusion of 600 mg/m2 at days 1–2. Treatment was repeated in 2-week intervals. The expressions of ERCC1, TS, and GSTP1 of primary tumors were examined by immunohistochemistry.

Results: The positive rates of ERCC1, TS, and GSTP1 were 70.3%, 29.7%, and 50.0%, respectively. The patients without ERCC1 expression were more likely to respond to chemotherapy (P = 0.045). There were no significant differences between response and TS or GSTP1 expression pattern (P = 0.813, P = 0.305, respectively). Median overall survival (OS) was significantly longer in patients without ERCC1 expression (P = 0.0396). TS or GSTP1 expression were not related to survival (P = 0.4578, P = 0.8121, respectively). Multivariate analysis revealed that ERCC1 expression significantly impacted on OS (hazard ratio 1.92, P = 0.037).

Conclusion: Immunohistochemical studies for ERCC1 may be useful in prediction of the clinical outcome in advanced gastric cancer patients treated with 5-FU and oxaliplatin.

Key words: ERCC1, Gastric Cancer, Oxaliplatin

Received for publication September 3, 2006. Revision received October 18, 2006. Accepted for publication October 18, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
C. L Ronchi, S. Sbiera, L. Kraus, S. Wortmann, S. Johanssen, P. Adam, H. S Willenberg, S. Hahner, B. Allolio, and M. Fassnacht
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy
Endocr. Relat. Cancer, September 1, 2009; 16(3): 907 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. R. Bhagwat, V. Y. Roginskaya, M. B. Acquafondata, R. Dhir, R. D. Wood, and L. J. Niedernhofer
Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human Tissue
Cancer Res., September 1, 2009; 69(17): 6831 - 6838.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan
Biomarkers of response to therapy in oesophago-gastric cancer
Gut, January 1, 2009; 58(1): 127 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Kim, K.-J. Cho, G. Y. Kwon, S.-I. Park, Y. H. Kim, J. H. Kim, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, et al.
Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
Clin. Cancer Res., July 1, 2008; 14(13): 4225 - 4231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Smith, D. Su, I. A. Rigault de la Longrais, P. Schwartz, M. Puopolo, T. J. Rutherford, G. Mor, H. Yu, and D. Katsaros
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
J. Clin. Oncol., November 20, 2007; 25(33): 5172 - 5179.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-C. Soria
ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2648 - 2649.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.